Company Announcements

Metagenomi Reclaims Rights, Shifts Strategy Post-Moderna Partnership

An announcement from Metagenomi, Inc. (MGX) is now available.

Metagenomi, Inc. and ModernaTX, Inc. have mutually terminated their partnership initially established in 2021 for developing in-vivo genome editing therapies. As a result, Metagenomi reclaims full rights to its genome editing systems. Since the termination, Metagenomi is no longer eligible to receive any future payments from Moderna. Additionally, Metagenomi has updated its investor presentation and plans to discuss these changes in an investor call, signaling a new phase in the company’s strategic direction.

See more insights into MGX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyMetagenomi reports Q3 EPS (51c), consensus (78c)
TheFlyMetagenomi presents poster on genome editing at ESGCT
Joseph E. LeviMetagenomi, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP for More Information – MGX
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App